Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Method To Efficiently Produce Less Toxic Drugs Using Organic Molecules Discovered By NTU Professor
Nanyang Technological University (NTU)"s Associate Professor Zhong Guofu has made a significant contribution to the field of organic chemistry, in particular the study of using small organic molecules as catalysts, in the synthesis process called organocatalysis. Such synthesis process takes place for example, during the production of chiral drugs.
generic viagra online
Perceived Cancer Risks May Not Reflect Actual Risks Or Prevention Needs
Working with a population of individuals at risk for gastrointestinal cancers, researchers at Fox Chase Cancer Center have learned that many people misjudge their actual degree of cancer risk and, therefore, their true need for prevention support. Strategies for accurately assessing cancer risk are critical for appropriately targeting educational, counseling, and diagnostic res to prevent cancer in as many individuals as possible, the investigators say.
News of the day
Considering Combination Versus Sequential Chemotherapy In Metastatic Breast Cancer
Both combination and sequential single-agent chemotherapy are reasonable options to treat metastatic breast cancer, but the choice between the two should ultimately be based on patient- and disease-related factors, according to a new commentary published online August 5 in the Journal of the National Cancer Institute.
Mental Health

Roche Launches Complete Detection Kit For Influenza A /H1N1 On LightCycler(R) System

Roche Applied Science announced the availability of a new detection kit for the Influenza A/H1N1 virus. The detection kit is offered for use in life science research. Roche currently is filing to get approval of the local health authorities worldwide for use of the kit in emergency situations. The kit runs on Roche÷´s LightCycler® 480 II, 2.0, and 1.5 systems. It was evaluated with virus positive sample materials and selectively identifies the new Influenza A H1N1 virus. Compared with other detection kits, it features a couple of advantages in regard to efficiency and handling. "The design of the new detection kits benefitted very much from information we got out of our manifold research cooperations. We are glad of our contribution in supplying fast and reliable tools for the detection of Influenza A/H1N1 to the research community," said Manfred Baier, Head of Roche Applied Science. Applied Science offers a variety of platforms that can be used to help identify the Influenza A H1N1 virus, including Nucleic Acid Purification, Real-Time PCR, Microarrays and Sequencing systems. The company is in close contact with various research institutions and test centers worldwide providing assistance in the detection and characterization of Influenza A H1N1 virus. Currently, there is no human vaccine on the market that protects against Influenza A H1N1 infection. Standard therapy for the disease includes treatment with antiviral drugs like Tamiflu or Relenza. For more information on Influenza A H1N1 please visit www.who.int. Roche


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009